Dr. Irina Babina's career shift from academic research to CEO of Conquer was fueled by her frustration with promising science failing to reach patients. This desire for tangible, results-driven application is a key motivator for scientists moving into the commercial bio-tech space to create real-world impact.
The future of personalized oncology isn't just about matching one drug to one patient. It's about classifying patients into three key groups: those who respond to everything, those who respond to nothing (and should enter clinical trials), and a crucial middle group where digital twins can identify the specific treatment that will make a difference.
Conquer's Farsight Twin can predict a patient's response to a novel drug, standard of care, and the combination therapy separately. This allows pharma companies to determine if a positive response in an early-phase trial is truly driven by their new asset or just the background therapy, providing crucial efficacy data.
Computational techniques from astrophysics, designed to model unobservable phenomena like dark matter, are now being used to understand cancer's hidden properties like its evolutionary dynamics and heterogeneity. This treats cancer not as a static disease but as a dynamic, evolving structure that can be tracked and anticipated.
Bayesian computation excels in handling uncertainty by using probabilistic modeling, allowing it to adapt to new information in real-time. This is analogous to a GPS recalculating a route, whereas traditional frequentist models are like a static paper map, requiring a complete redrawing for new scenarios.
By training on data across many cancer types ("pan-cancer"), AI models learn universal biological principles. This approach allows them to generalize learnings from large, common cancer datasets to significantly improve prediction accuracy for rare cancers, which often suffer from a lack of specific data for training effective models.